Views: 1,409 | Downloads:
104
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
The Study of Cisplatin and Vinorelbine in Metastatic Uterine Cervical Cancer
Kamnerdsupaphon P 
,
Chitapanarux I ,
Tharavichitkul E ,
Sukthomya V ,
Lorvidhaya V
,
Chitapanarux I ,
Tharavichitkul E ,
Sukthomya V ,
Lorvidhaya V Objective: To determine the therapeutic efficacy of cisplatin in combination with vinorelbine in the treatment
of patients with metastatic cervical cancer.
Material and Method: a total of 17 patients were enrolled in the present study. The median age was 46 years
(38-65). There were 6 patients who were diagnosed as stage IVB cervical cancer without previous treatment.
The patients were planned to receive cisplatin 80 mg/m2 on day 1 and vinorelbine at 30 mg/m2 on day 1 and
8 every 3 weeks.
Results: Fifteen patients were available for evaluation: 2 (13.3%) achieved a complete response, 8 (53.4%)
partial responses, 3 (20%) stable diseases and 2 (13.3%) progression of the disease. Myelosuppression
was the major toxicity. Grade 3-4 toxicities include 66.7% hemoglobin and 26.7% neutropenia. No other
significant side effects were found.
Conclusion: Cisplatin-vinorelbine is an active and well-tolerated regimen in metastatic cervical carcinoma.
These results require confirmation.
Keywords: Uterine cervical neoplasms, Cisplatin, Vinblastine, Vinorelbine
of patients with metastatic cervical cancer.
Material and Method: a total of 17 patients were enrolled in the present study. The median age was 46 years
(38-65). There were 6 patients who were diagnosed as stage IVB cervical cancer without previous treatment.
The patients were planned to receive cisplatin 80 mg/m2 on day 1 and vinorelbine at 30 mg/m2 on day 1 and
8 every 3 weeks.
Results: Fifteen patients were available for evaluation: 2 (13.3%) achieved a complete response, 8 (53.4%)
partial responses, 3 (20%) stable diseases and 2 (13.3%) progression of the disease. Myelosuppression
was the major toxicity. Grade 3-4 toxicities include 66.7% hemoglobin and 26.7% neutropenia. No other
significant side effects were found.
Conclusion: Cisplatin-vinorelbine is an active and well-tolerated regimen in metastatic cervical carcinoma.
These results require confirmation.
Keywords: Uterine cervical neoplasms, Cisplatin, Vinblastine, Vinorelbine
Download:
PDF